Ariad Pharmaceuticals Inc fka ARIA

[Jesspro]

NON CML INDICATIONS as posted on another board - just a reminder

There are plenty of potential catalysts that could increase ARIA pps by several fold over the next (e.g.) 2 years. As with almost any targeted drug today, potential competition is likely to increase as ponatinib advances. But the safety issue is essentially put to bed and so the main question is effectiveness at (e.g.) 30 mg. I have placed my bet since only a subset of these indications for ponatinib need be effective to bring significant value to ARIA. AP113 gilds the lily.

Ponatinib studies registered at clintrials.gov today:

"Recruiting" designation:
1. Frontline for Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP)
2. Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers
3. Hyper-CVAD and Ponatinib in Ph-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)
4. Advanced NSCLC w/ RET Translocations
5. Advanced Medullary Thyroid Cancer

"Not yet recruiting" designation:
6. Treatment of FGFR Mutation Positive Recurrent or Persistent Endometrial Carcinoma
7. Treating Patients With Advanced Biliary Cancer With FGFR2 Fusions
8. Treating Patients With Refractory Metastatic Cancers and Genetic Alterations
9. Front-line Treatment of Adult Affected of Philadelphia+/BCR-ABL+ Acute Lymphoblastic Leukemia (ALL) Less